1-3 of 3
Nancy Day, Ph.D.
Close
Sort by
Journal Articles

Genomic Pathways and Potential Therapeutic Targets in Pediatric Burkitt Lymphoma (PBL): A Children's Oncology Group Report

Mitchell S. Cairo, MD, Nancy Day, Ph.D., Stanton Goldman, MD, Warren G. Sanger, PhD, Lauren Harrison, RN, MSN, Megan S. Lim, MD, PhD, Rodney R. Miles, MD, PhD, Sherrie L. Perkins, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 1587.
https://doi.org/10.1182/blood.V118.21.1587.1587
Published: 2011
Journal Articles

DLEU1 siRNA Gene Knockdown IN BURKITT LYMPHOMA (bl) IS ASSOCIATED with A SIGNIFICANT Decrease IN Cyclophosphamide (CY) and/or Rituximab Induced Apoptosis: Mechanism of Drug Resistance in BL.

Nancy Day, Ph.D., Janet Ayello, MS, MT, Carmella van de Ven, MA, Megan S Lim, MD, PhD, Sherrie L. Perkins, MD, PhD, Warren Sanger, PhD, Lauren Harrison, RN, Stanton Goldman, MD, Mitchell S. Cairo, MD
Journal: Blood
Blood (2009) 114 (22): 1928.
https://doi.org/10.1182/blood.V114.22.1928.1928
Published: 2009
Journal Articles

Global Proteomic Profiling of Endemic Versus Sporadic Epstein-Barr Virus (EBV) Positive Burkitt Lymphoma (BL).

Nader El-Mallawany, MD, Janet Ayello, MS, MT, Nancy Day, Ph.D., Carmella van de Ven, MS, Kevin P Conlon, Damian Fermin, Venkatesha Basrur, Kojo S.J. Elenitoba-Johnson, Megan S Lim, MD, PhD, Mitchell S. Cairo, MD
Journal: Blood
Blood (2009) 114 (22): 4779.
https://doi.org/10.1182/blood.V114.22.4779.4779
Published: 2009